25,381 Shares in Becton, Dickinson and Company $BDX Bought by M. Kulyk & Associates LLC

M. Kulyk & Associates LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel.com reports. The firm bought 25,381 shares of the medical instruments supplier’s stock, valued at approximately $3,841,000.

Other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the last quarter. Camelot Portfolios LLC lifted its position in shares of Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares during the last quarter. Atlantic Union Bankshares Corp boosted its stake in Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after purchasing an additional 57 shares during the period. WPG Advisers LLC grew its holdings in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares during the last quarter. Finally, Oakworth Capital Inc. grew its holdings in Becton, Dickinson and Company by 4.3% in the 4th quarter. Oakworth Capital Inc. now owns 1,555 shares of the medical instruments supplier’s stock valued at $302,000 after buying an additional 64 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Bank of America lowered their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. TD Cowen boosted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Finally, UBS Group initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Trading Down 0.5%

Becton, Dickinson and Company stock opened at $181.17 on Wednesday. The business has a 50 day moving average price of $159.06 and a two-hundred day moving average price of $161.12. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a market cap of $49.92 billion, a price-to-earnings ratio of 54.57, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.